eMJA     The Medical Journal of Australia

Home | Issues | eMJA shop | My account | Classifieds | Contact | More... | Topics | Search   

Primary stenting in selected patients with AMI appears to be more effective than PTCA or fibrinolytic therapy,^2,3,6-18 but not all infarct-related arteries are suitable for stenting. A primary stenting strategy incorporating primary stenting, PTCA, coronary artery bypass grafting (CABG) or medical treatment (except fibrinolytic therapy) is expected to cater for all patients. We examined prospectively the feasibility and clinical outcomes to 6 months of a primary stenting strategy in patients with AMI who were eligible for fibrinolysis.

Patient selection
Patients included: 102 patients fulfilled GUSTO criteria for AMI,⁵ and were eligible for fibrinolysis. A lower age limit was imposed during the first half of the study (during the learning curve for the stenting team), and patients with previous CABG were excluded because stenting was initially thought to be less effective in vein-graft occlusion. Accordingly, the first 50 patients were under 70 years and had not had CABG. The following 52 patients, two of whom had had CABG, were under 80 years.

Patients excluded: Reasons for non-entry to the study in 92 patients were age limit exceeded (over 70 years, 47 patients; over 80 years, 23 patients); transfer from other hospitals for primary intervention (5 patients); not eligible for fibrinolysis, including two with cardiogenic shock (8 patients); no vascular access (2 patients); prior CABG (2 patients); cardiogenic shock (1 patient); eligible but refused (2 patients); and eligible but interventional cardiologist unavailable (2 patients).

Ethical approval
The protocol was approved by the hospital's Human Research and Ethics Committee. All patients gave informed consent.

Study protocol
Patients were given aspirin (300 mg), ticlopidine (500 mg) and an intravenous heparin bolus (150 U/kg), and transferred immediately to the catheterisation laboratory, or, out of working hours, as soon as the interventional team arrived. Low-osmolar ionic contrast medium (sodium ioxaglate) was used to minimise thromboembolic complications.¹⁹

Blood flow was re-established in the occluded infarct-related arteries with Magnum (Schneider, Bulach, Switzerland) 0.014 inch wire through a 6 French (2 mm diameter) guide. Placement of a stainless steel stent (the majority were GFX (Arterial Vascular Engineering, Santa Rosa, Calif, USA) by high pressure balloon inflation (> 10 atmospheres) was attempted in vessels with a reference segment diameter of more than 2.5 mm and a lesion length of less than 32 mm. Thrombus was not considered a contraindication to stenting. Fibrinolytic therapy was not given.

Medical treatment only was given (aspirin, heparin, -blockers) if, after cardiac catheterisation, the infarct-related artery was patent with normal brisk flow (ie, grade 3 flow as defined by the Thrombolysis in Myocardial Infarction [TIMI] trial²⁰), and had residual stenosis of less than 50% of vessel diameter.

Emergency (immediate) or inhospital CABG was performed for left main coronary artery and/or severe triple-vessel disease, and PTCA was performed when the diameter of the infarct-related artery was less than 2.5 mm.

A glycoprotein IIb/IIIa receptor antagonist (abciximab) was given to 23 of the 102 patients: 11 patients having primary PTCA, 3 patients in whom reflow did not occur, and 9 patients with persistent filling defects or a long stented segment (> 18 mm). Further heparin was given if activated clotting time (for monitoring high dose heparin) was under 300 seconds. No further heparin was given after the procedure and patients were mobilised 12 hours after femoral sheath removal.

Ticlopidine (250 mg daily) was administered for 4 weeks and patients were monitored for side effects (neutropenia, thrombocytopenia).

All patients were followed up by their general practitioner and specialist physician. Follow-up for the trial was at 6 weeks and 6 months; patients completed questionnaires or, if necessary, were interviewed by phone.

Outcome measures
Study outcome measures were major adverse cardiac and cerebrovascular events: death, reinfarction, cerebrovascular accident (CVA) and repeat target lesion revascularisation, in hospital, and at 6 weeks and 6 months.

Reinfarction was defined as recurrent ischaemic symptoms with changes noted on the electrocardiogram (ECG) (ST-segment elevation or new Q waves) and elevation in the level of creatine kinase (MB fraction) to more than twice the upper limit (normal range, 0-7 µg/L) or any rise above a previously elevated level.

CVA was defined as new persistent (> 24 hours) neurological deficit consistent with a stroke, confirmed by a physician or by computed tomography scan of the brain.

Patency of the infarct-related artery was determined by TIMI classification.²⁰

Minor inhospital adverse events included bleeding requiring blood transfusion, vascular complications and new-onset heart failure.

Successful procedural outcome was a patent infarct-related artery with residual stenosis of less than 30% of vessel diameter (without major adverse cardiac and cerebrovascular events in hospital), or uncomplicated CABG.

There were no inhospital deaths, reinfarctions or CVAs. Four patients (4%) required repeat target lesion revascularisation (three had been treated initially with PTCA and one with stenting). Unscheduled recatheterisation was performed in another four patients with chest pain, without ECG changes. All showed a widely patent stent. No patient developed recurrent chest pain with ECG changes while in hospital.

Minor inhospital events included blood transfusion, all after CABG (7/102; 7%), new-onset heart failure (2/102; 2%), and femoral artery pseudoaneurysm requiring surgical repair (2/102; 2%).

For more information see flow chart

Six-week and 6-month follow-up
Follow-up was completed for all patients due for follow-up at 6 weeks (n = 102) and at 6 months (n = 58).

At 6 weeks no deaths or CVAs had occurred. One patient had had a reinfarction after a subacute stent thrombosis on Day 10. He underwent successful repeat PTCA (reperfusion at sites other than the target lesion was not performed). Major adverse cardiac or cerebrovascular events had occurred in 5/102 patients: one had a reinfarction after discharge and four required repeat target lesion reperfusion.

At 6 months, still no deaths had occurred, and there had been no further reinfarctions or CVAs. Clinical restenosis requiring repeat target lesion revascularisation occurred in an additional 6/58 patients (10%). Revascularisation at a new site of stenosis was performed in 1/58 patients (2%).

No deaths, reinfarctions or CVAs had occurred since discharge, and at 6 months there had not been any requirement for revascularisation in 51/58 patients (88%).

Hospital stay
Mean hospital stay was 5.0 days (95% confidence interval (CI), 4.5-5.5 days). Mean coronary care, intensive care and general ward stays were 1.5 (95% CI, 1.4-1.6), 0.5 (95% CI, 0.3-0.7) and 3.0 days (95% CI, 2.7-3.3), respectively. Median hospital stay was 3 days.

Time delays
Time delays between the onset of chest pain and re-establishment of TIMI 3 flow of the infarct-related artery are shown in Box 2. Although 58% of patients presented out of working hours, only 10% of "call-backs" for the intervention team took place between 23:00 and 04:00.

Coronary artery patency with the primary stenting strategy was achieved in 95% of patients, similar to reports for primary stenting in selected patients,^14-18 but higher than reported for primary PTCA (73%-87%) and fibrinolysis with t-PA (54%).^1,3,7-9 Interestingly, 25% of patients in our study had TIMI 3 flow at cardiac catheterisation, a rate higher than reported by some investigators (7%-11%)¹⁴ and similar to rates after fibrinolysis with streptokinase (29%-32%). We gave a 150 U/kg bolus dose of intravenous heparin, which may explain this difference.²¹

Our results compare favourably with those of other primary stenting studies.^14-18 A 30-day rate of 3% for major adverse cardiac and cerebrovascular events has been reported for patients undergoing primary stenting.^14,15 However, in one of these studies,¹⁴ up to 15% of patients screened were excluded, owing to unsuitable anatomy of the infarct-related artery (eg, diffuse disease), and events in such patients were not included. Several studies report outcomes of patients treated by primary PTCA separately to those treated by stenting,^14-18 making it difficult to directly compare the results with those of trials of fibrinolytic therapy in which all patients are included. We included all patients eligible for fibrinolysis who fulfilled the inclusion criteria in our analysis. This allows a more realistic impression of the benefits of a primary stenting strategy, as our data can be compared with data from trials of fibrinolytic therapy (the alternative treatment offered to all patients at enrolment).

Feasibility
In order to test the feasibility of a primary stenting strategy (our main aim), our emergency department had to triage patients without delay and the interventional team had to respond swiftly at all hours. Time delays (mean and median) from arrival at the emergency department to notification of the interventional team (42 and 35 minutes), from notification of the team to TIMI 3 flow (64 and 60 minutes), and from arrival at the emergency department to TIMI 3 flow (106 and 95 minutes), compare well with time delays from trials of fibrinolysis and angioplasty. The GUSTO investigators reported a median interval of 64 minutes from randomisation to administration of fibrinolytic therapy,⁵ and the GUSTO IIb investigators reported a median interval of 114 minutes from emergency department arrival to first balloon inflation in the primary PTCA group.¹⁰

Patency rates are reported 90 minutes after starting fibrinolytic therapy.¹ Assuming a mean delay of 42 minutes in the emergency department to administration of fibrinolytic therapy, the equivalent inhospital delay from emergency department arrival to TIMI 3 flow with fibrinolytic therapy would be a mean of 132 minutes (but TIMI 3 flow would actually be achieved in only 54% of patients). We achieved TIMI 3 flow in 95% of patients within a mean of 106 minutes of arrival at the emergency department.

Limitations of the study
This study was a non-randomised, single-centre study with a small sample size. For the first half of the study, enrolment was restricted to a relatively low risk group under 70 years of age without previous CABG. Interventions were performed by two experienced operators. Thus, comparison of our data with results from much larger trials of fibrinolytic therapy must be performed with caution.

Conclusions
A primary stenting strategy is feasible and safe, with an excellent clinical outcome to 6 months. We are now planning a larger, randomised phase of this study, with patients from the Northern Sydney Area Health Region (which includes four district hospitals) outside the Royal North Shore Hospital (RNSH) catchment area being allocated at random to either conventional treatment with fibrinolytic therapy at the district hospital or a primary stenting strategy at RNSH. We hypothesise that mechanical reperfusion therapy will prove the superior strategy because of its higher early patency rate³ and offset any disadvantages of the small time difference imposed by a longer ambulance journey.

1. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-1622.
2. Califf RM, White H, Van de Werf F, et al. One-year results from the global utilization of streptokinase and TPA for occluded coronary arteries (GUSTO-I) trial. Circulation 1996; 94: 1233-1238.
3. Ross AM, Coyne KS, Moreyra E, et al, for the GUSTO-I Angiographic Investigators. Extended mortality benefit of early postinfarction reperfusion. Circulation 1998; 97: 1549-1556.
4. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trials of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-360.
5. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.
6. Meijer A, Verheugt FWA, Werter CJPJ, et al. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Circulation 1993; 87: 1524-1530.
7. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993; 328: 673-679.
8. Zijlstra F, de Boer JM, Hoorntje JC, et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993; 328: 680-684.
9. Gibbons RJ, Holmes DR, Reeder GS, et al. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 1993; 328: 685-691.
10. The GUSTO-IIb angioplasty substudy investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997; 336: 1621-1628.
11. Stone GW, Grines CL, Browne KF, et al. Predictors of in-hospital and 6 month outcome after acute myocardial infarction in the reperfusion era: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. J Am Coll Cardiol 1995; 25: 370-377.
12. Ohman EM, Califf RM, Topol EJ, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990; 82: 781-791.
13. Weaver WD, Simes J, Amadeo B, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction. A quantitative review. JAMA 1997; 278: 2093-2098.
14. Stone GW, Brodie B, Griffin J, et al. Prospective, multicentre study of the safety and feasibility of primary stenting in acute myocardial infarction: In-hospital and 30-day results of the PAMI Stent Pilot Trial. J Am Coll Cardiol 1998; 31: 23-30.
15. Suryapranata H, van't Hof AWJ, Hoorntje JCA, et al. Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction. Circulation 1998; 97: 2502-2505.
16. Antoniucci D, Santoro GM, Bolognese L, et al. A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction. Results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) Trial. J Am Coll Cardiol 1998; 31: 1234-1239.
17. Saito S, Hosokawa G. Primary Palmaz-Schatz stent implantation for acute myocardial infarction: the final results of Japanese PASTA (Primary Angioplasty vs Stent Implantation in AMI in Japan) trial [abstract]. Circulation 1997; 96: A3320.
18. Serruys PW, Garcia-Fernandez E, Kiemeney F, et al. Stenting in acute MI: A pilot study as preamble to a randomized trial comparing balloon angioplasty and stenting [abstract]. Circulation 1997; 96: A1822.
19. Grines CL, Schreiber TL, Savas V, et al. A randomized trial of low osmolar ionic versus nonionic contrast media in patients with myocardial infarction or unstable angina undergoing percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1996; 27: 1381-1386.
20. The TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) Trial: Phase 1 findings. N Engl J Med 1985; 312: 1073-1092.
21. Verheugt FWA, Liem A, Zijlstra F, et al. High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the heparin in early patency (HEAP) pilot study. J Am Coll Cardiol 1998; 31: 289-293.

Reprints: Dr G I C Nelson, Department of Cardiology, Royal North Shore Hospital, St Leonards, NSW 2065.

©MJA 1999
Make a comment

Other articles have cited this article:

  James W Leitch. Changing times in the treatment of myocardial infarction Med J Aust 2003; 178 (8): 367-368. [Editorials] <http://www.mja.com.au/public/issues/178_08_210403/lei10075_fm-1.html>

Readers may print a single copy for personal use. No further reproduction or distribution of the articles should proceed without the permission of the publisher. For permission, contact the Australasian Medical Publishing Company.
Journalists are welcome to write news stories based on what they read here, but should acknowledge their source as "an article published on the Internet by The Medical Journal of Australia <http://www.mja.com.au>".
<URL: http://www.mja.com.au/> © 1999 Medical Journal of Australia.
We appreciate your comments.